Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 19/20 | 0.55 |
| ▸ | MMP13 | P45452 | 3/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.52 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29250257 | 1.00 | ADAMTS5 (0.55) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23745214 | 1.00 | ADAMTS5 (0.55) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL29835185 | 0.92 | ADAMTS5 (0.54) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL29835157 | 0.92 | ADAMTS5 (0.54) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23745405 | 0.92 | ADAMTS5 (0.54) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL29250233 | 0.92 | ADAMTS5 (0.54) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23727481 | 0.88 | ADAMTS5 (0.58) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23727483 | 0.88 | ADAMTS5 (0.58) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23745412 | 0.86 | ADAMTS5 (0.65) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 | |
| SCHEMBL23745206 | 0.86 | ADAMTS5 (0.53) | ADAMTS5MMP13ADAM17MMP2ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-115052596-B | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| CN-115052596-A | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885MMP13 23/4885ADAM17 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.